AR018501A1 - Derivados de la dolastatina 15 - Google Patents

Derivados de la dolastatina 15

Info

Publication number
AR018501A1
AR018501A1 ARP980103445A ARP980103445A AR018501A1 AR 018501 A1 AR018501 A1 AR 018501A1 AR P980103445 A ARP980103445 A AR P980103445A AR P980103445 A ARP980103445 A AR P980103445A AR 018501 A1 AR018501 A1 AR 018501A1
Authority
AR
Argentina
Prior art keywords
group
amino
formula
present
amino group
Prior art date
Application number
ARP980103445A
Other languages
English (en)
Spanish (es)
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of AR018501A1 publication Critical patent/AR018501A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP980103445A 1997-07-18 1998-07-15 Derivados de la dolastatina 15 AR018501A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/896,394 US6143721A (en) 1997-07-18 1997-07-18 Dolastatin 15 derivatives

Publications (1)

Publication Number Publication Date
AR018501A1 true AR018501A1 (es) 2001-11-28

Family

ID=25406130

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980103445A AR018501A1 (es) 1997-07-18 1998-07-15 Derivados de la dolastatina 15

Country Status (32)

Country Link
US (6) US6143721A (enExample)
EP (1) EP0991658B1 (enExample)
JP (4) JP4508413B2 (enExample)
KR (1) KR100579748B1 (enExample)
CN (1) CN1268636C (enExample)
AR (1) AR018501A1 (enExample)
AT (1) ATE314387T1 (enExample)
AU (1) AU750120B2 (enExample)
BG (1) BG65212B1 (enExample)
BR (1) BR9810911A (enExample)
CA (1) CA2296036C (enExample)
CO (1) CO4990967A1 (enExample)
CY (1) CY1107047T1 (enExample)
CZ (1) CZ303045B6 (enExample)
DE (1) DE69832982T2 (enExample)
DK (1) DK0991658T3 (enExample)
ES (1) ES2258819T3 (enExample)
HR (1) HRP980397A2 (enExample)
HU (1) HU228996B1 (enExample)
ID (1) ID24669A (enExample)
IL (1) IL133784A (enExample)
MY (1) MY135057A (enExample)
NO (1) NO326827B1 (enExample)
NZ (1) NZ502296A (enExample)
PL (1) PL197884B1 (enExample)
PT (1) PT991658E (enExample)
RU (1) RU2195462C2 (enExample)
SK (1) SK286581B6 (enExample)
TR (2) TR200103545T2 (enExample)
TW (1) TW533217B (enExample)
WO (1) WO1999003879A1 (enExample)
ZA (1) ZA986358B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010009901A1 (en) * 1996-12-11 2001-07-26 Basf Aktiengesellschaft Germany Antineoplastic peptides
US6143721A (en) * 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
AU2001227375A1 (en) 2000-02-08 2001-08-20 Herbert T. Nagasawa N-terminal d(-)-penicillamine peptides as aldehyde sequestration agents
US7256257B2 (en) * 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6884869B2 (en) * 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7064211B2 (en) * 2002-03-22 2006-06-20 Eisai Co., Ltd. Hemiasterlin derivatives and uses thereof
KR101208266B1 (ko) * 2002-03-22 2012-12-05 에자이 알앤드디 매니지먼트 가부시키가이샤 헤미아스텔린 유도체 및 이의 용도
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
EP2478912B1 (en) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
JP2008522624A (ja) * 2004-12-09 2008-07-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘミアスタリン（ｈｅｍｉａｓｔｅｒｌｉｎ）アナログを使用する癌治療におけるチューブリンのアイソタイプのスクリーニング
JP4954983B2 (ja) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Ｂｉｒドメイン結合化合物
CN101535300B (zh) 2006-05-16 2014-05-28 埃格拉医疗公司 Iap bir域结合化合物
PE20090943A1 (es) 2007-07-16 2009-08-05 Genentech Inc Anticuerpos anti-cd79b e inmunoconjugados
EP2176295B1 (en) 2007-07-16 2014-11-19 Genentech, Inc. Humanized anti-cd79b antibodies and immunoconjugates and methods of use
DE102007039706A1 (de) 2007-08-22 2009-02-26 Erhard Prof. Dr.-Ing. Kohn Chemischer Sensor auf Diamantschichten
KR101607346B1 (ko) 2008-01-31 2016-03-29 제넨테크, 인크. 항-ｃｄ７９ｂ 항체 및 면역접합체 및 사용 방법
MX2012006877A (es) 2009-12-18 2012-08-31 Idenix Pharmaceuticals Inc Inhibidores de virus de hepatitis c de arileno o heteroarileno 5, 5 - fusionado.
KR20130009760A (ko) 2010-02-10 2013-01-23 이뮤노젠 아이엔씨 Ｃｄ２０ 항체 및 이의 용도
US9284350B2 (en) 2010-02-12 2016-03-15 Pharmascience Inc. IAP BIR domain binding compounds
CA2891280C (en) 2012-11-24 2018-03-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
US10464955B2 (en) 2014-02-28 2019-11-05 Hangzhou Dac Biotech Co., Ltd. Charged linkers and their uses for conjugation
HUE049175T2 (hu) 2014-09-23 2020-09-28 Hoffmann La Roche Eljárás anti-CD79b immunkonjugátumok alkalmazására
CA2989269C (en) 2015-06-15 2020-09-22 Robert Yongxin Zhao Hydrophilic linkers for conjugation of a cytotoxic agent or chromophore molecule to a cell-binding molecule
NZ739830A (en) 2015-07-12 2021-12-24 Hangzhou Dac Biotech Co Ltd Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
KR20220150408A (ko) 2016-11-14 2022-11-10 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
CN118119409A (zh) 2021-09-03 2024-05-31 东丽株式会社 癌的治疗和/或预防用药物组合物
EP4426727A2 (en) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816444A (en) * 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US4879278A (en) * 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
WO1993003054A1 (fr) * 1991-08-09 1993-02-18 Teikoku Hormone Mfg. Co., Ltd. Nouveau derive de tetrapeptide
AU3777593A (en) * 1992-02-26 1993-09-13 Paul C. Clark System for protecting computers via intelligent tokens or smart cards
US5533097A (en) * 1992-02-26 1996-07-02 Motorola, Inc. Portable communication system comprising a local and wide area communication units which can store a communication when the wide area communication system is not available
CA2136339C (en) * 1992-05-20 2008-02-05 Andreas Haupt Derivatives of dolastatin
US5831002A (en) * 1992-05-20 1998-11-03 Basf Aktiengesellschaft Antitumor peptides
PL178766B1 (pl) * 1992-12-16 2000-06-30 Basf Ag Nowe peptydy
US5554993A (en) * 1994-01-04 1996-09-10 Panasonic Technologies, Inc. Global position determining system and method
US5504191A (en) * 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5530097A (en) * 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5554725A (en) * 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
US5663149A (en) * 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5618232A (en) * 1995-03-23 1997-04-08 Martin; John R. Dual mode gaming device methods and systems
US5970143A (en) * 1995-11-22 1999-10-19 Walker Asset Management Lp Remote-auditing of computer generated outcomes, authenticated billing and access control, and software metering system using cryptographic and other protocols
US5807984A (en) * 1995-11-09 1998-09-15 Basf Aktienegesellschaft Oligopeptides, the preparation and use thereof
TW474946B (en) * 1995-12-15 2002-02-01 Basf Ag Novel compounds, the preparation and use thereof
AU728161B2 (en) * 1997-01-10 2001-01-04 Silicon Gaming, Inc. Method and apparatus using geoographical position and a universal time to determination means to provide authenticated, secure, on-line communication between remote gaming locations
US6143721A (en) * 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
US6554705B1 (en) * 1997-08-22 2003-04-29 Blake Cumbers Passive biometric customer identification and tracking system
US6629591B1 (en) * 2001-01-12 2003-10-07 Igt Smart token
US6438382B1 (en) * 2001-02-14 2002-08-20 Telefonaktiebolaget Lm Ericsson (Publ.) Expedited location determination in analog service areas

Also Published As

Publication number Publication date
US20100099843A1 (en) 2010-04-22
US7084110B2 (en) 2006-08-01
HU228996B1 (hu) 2013-07-29
HRP980397A2 (en) 1999-04-30
IL133784A (en) 2005-09-25
CN1268636C (zh) 2006-08-09
US20060270606A1 (en) 2006-11-30
SK187999A3 (en) 2000-09-12
BR9810911A (pt) 2000-08-01
TR200000132T2 (tr) 2000-05-22
SK286581B6 (sk) 2009-01-07
BG65212B1 (bg) 2007-07-31
NO20000231D0 (no) 2000-01-17
WO1999003879A1 (en) 1999-01-28
JP4508413B2 (ja) 2010-07-21
CZ303045B6 (cs) 2012-03-07
JP2001515010A (ja) 2001-09-18
IL133784A0 (en) 2001-04-30
US7662786B2 (en) 2010-02-16
JP2009137967A (ja) 2009-06-25
JP2012211164A (ja) 2012-11-01
CA2296036A1 (en) 1999-01-28
CO4990967A1 (es) 2000-12-26
HUP0004234A2 (hu) 2001-05-28
HUP0004234A3 (en) 2001-08-28
ZA986358B (en) 2000-01-17
ATE314387T1 (de) 2006-01-15
US20030153505A1 (en) 2003-08-14
PL197884B1 (pl) 2008-05-30
AU750120B2 (en) 2002-07-11
US6143721A (en) 2000-11-07
CZ2000176A3 (en) 2001-06-13
US20130046077A1 (en) 2013-02-21
RU2195462C2 (ru) 2002-12-27
PT991658E (pt) 2006-05-31
ES2258819T3 (es) 2006-09-01
DE69832982T2 (de) 2006-08-24
DK0991658T3 (da) 2006-05-15
CY1107047T1 (el) 2012-09-26
JP5122429B2 (ja) 2013-01-16
TW533217B (en) 2003-05-21
NO326827B1 (no) 2009-02-23
EP0991658A1 (en) 2000-04-12
CN1264388A (zh) 2000-08-23
JP5047935B2 (ja) 2012-10-10
KR20010021998A (ko) 2001-03-15
JP2009137968A (ja) 2009-06-25
CA2296036C (en) 2007-05-01
MY135057A (en) 2008-01-31
AU8475898A (en) 1999-02-10
BG104089A (en) 2000-12-29
ID24669A (id) 2000-07-27
NZ502296A (en) 2002-02-01
PL338144A1 (en) 2000-09-25
EP0991658B1 (en) 2005-12-28
DE69832982D1 (de) 2006-02-02
TR200103545T2 (tr) 2002-06-21
KR100579748B1 (ko) 2006-05-15
HK1029125A1 (en) 2001-03-23
NO20000231L (no) 2000-01-17
US6458765B1 (en) 2002-10-01
US8163698B2 (en) 2012-04-24

Similar Documents

Publication Publication Date Title
AR018501A1 (es) Derivados de la dolastatina 15
GEP20012413B (en) Novel Substituted Cyclic Amino Acids as Pharmaceutical Agents
AR011957A1 (es) Derivados de dolastatina 15 con funcionalidades carbonilo y heterociclicas en el c-terminal
DE69030100D1 (de) Peptidderivat, verfahren zu dessen herstellung, sowie dieses enthaltende pharmazeutische zusammensetzung
DE3851776D1 (de) Verwendung von IGF-II zur Behandlung von Knochenkrankheiten.
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
ES2194835T3 (es) Agentes antitromboticos a base de tripeptidos.
DK0490772T3 (da) 1,4-disubstituerede piperaziner, fremgangsmåde til fremstilling heraf og farmaceutiske midler, der indeholder dem
BR0213139A (pt) Composto, método de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto e composição farmacêutica
PA8432901A1 (es) Compuestos de piridilpirrol
UY28279A1 (es) Fenacilo 2 -hidroxi - 3 - diaminoalcanos
ES2255063T3 (es) Inmunomodulador de polisacaridos capsular.
BR9607965A (pt) Composto composição farmacêutica e processo para tratar uma doença parasítica em um mamífero
ES2100222T3 (es) Derivados del acido aminoalcansulfonico y compuestos farmaceuticos a utilizar para prevenir o tratar afecciones cardiacas.
ES2149403T3 (es) Benciloxicarbonilguanidinas sustituidas como inhibidores del intercambiador de protones de sodio, procedimiento para su preparacion, su empleo como medicamento o agente de diagnostico, asi como medicamento que las contiene.
DE69818823D1 (de) Dipohosphonsäuresalze für die behandlung von osteoporose
BR0110396A (pt) Métodos para prevenir e tratar alopecia induzida por quimioterapia ou radioterapia
DK160316C (da) Analogifremgangsmaade til fremstilling af beta-casomorphinanaloge peptider samt pharmakologisk acceptable syreadditionssalte og metalkomplekser deraf
CO5640064A2 (es) Citomodilacion de peptidos para tratar cistitis intersticial
MX9300203A (es) Compuestos policiclicos disubstituidos y composicion farmaceutica que los contiene.
UY26911A1 (es) Ácidos amino (oxo) acéticos inhibidores de la proteina tirosina fosfatasa
ES2110057T3 (es) Composicion medicinal que contiene tcf-ii.
DE59409413D1 (de) Verwendung von n,s-diacetylcystein-ethylester (dacee) zur herstellung eines medikaments zur behandlung viraler erkrankungen
DE69939586D1 (de) Inhibitoren für die gefässneubildung
BR9906975A (pt) Composto, uso do mesmo, composição farmacêutica, e, processo para estimular a liberação do hormÈnio do crescimento pela pituitária de um mamìfero

Legal Events

Date Code Title Description
FG Grant, registration